Polymyalgia rheumatica (PMR) is an idiopathic inflammatory disease characterized by pain and stiffness around the shoulders, neck and hips. IL-6 is an important cytokine in the pathogenesis of the disease. Although glucocorticoids (GC) are the current basic treatment, approximately 50% of patients may experience relapses during treatment. There have been case reports of resistant patients treated with Tocilizumab (TCZ), but as there has been insuffi cient evidence, the 2015 EULAR-ACR did not include TCZ treatment in the PMR recommendations.Two cases of GC-resistant PMR cases where remission was obtained with TCZ treatment are presented in this paper.
Keywords:
Published on: Nov 20, 2017 Pages: 25-27
Full Text PDF
Full Text HTML
DOI: 10.17352/raoa.000007
CrossMark
Publons
Harvard Library HOLLIS
Search IT
Semantic Scholar
Get Citation
Base Search
Scilit
OAI-PMH
ResearchGate
Academic Microsoft
GrowKudos
Universite de Paris
UW Libraries
SJSU King Library
SJSU King Library
NUS Library
McGill
DET KGL BIBLiOTEK
JCU Discovery
Universidad De Lima
WorldCat
VU on WorldCat
PTZ: We're glad you're here. Please click "create a new query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."